FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compounds of formula: 
, wherein R represents H, or R consists of: 1) C1-6 alkyl and 2) 0 to 1 -OH groups; Y represents -Cl or -F; and X consists of: 1) a linear alkyl or alkynyl having 4 to 10 carbon atoms, and 2) 0 to 1 -OH groups. The invention also refers to an ophthalmologically acceptable fluid based on these compounds.
EFFECT: there are prepared new compounds that may be used in medicine for treating glaucoma.
9 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED CYCLOPENTANES, POSSESSING PROSTAGLANDIN ACTIVITY | 2009 |
|
RU2505530C2 |
| THERAPEUTIC SUBSTITUTED CYCLOPENTANES | 2009 |
|
RU2501789C2 |
| TLR7 AGONISTS | 2019 |
|
RU2817014C2 |
| PARTIAL AND FULL AGONISTS OF ADENOSINE RECEPTORS A | 2003 |
|
RU2340623C2 |
| COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
| BICYCLIC COMPOUND AND USING IT FOR MEDICAL APPLICATIONS | 2010 |
|
RU2540330C2 |
| SECONDARY AMINES AS RENIN INHIBITORS | 2007 |
|
RU2425032C2 |
| DERIVATIVES OF PROSTAGLANDINS WITHOUT ADVERSE EFFECTS FOR GLAUCOMA TREATMENT | 1998 |
|
RU2207858C2 |
| SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
| COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
